Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2019 Filed May 13, 2019 21:17 UTC |
MACMILLAN STEPHEN PDirector
|
GrantDeferred Stock Units · Derivative | 3,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-029001 · a4.xml · derivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,694 Underlying: Common Stock · 3,102 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: Reflects a value of $115,000 divided by the closing price of common stock on the date of grant. F5 · derivative.exercise_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F5 · derivative.expiration_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:17 UTC |
MACMILLAN STEPHEN PDirector
|
GrantDeferred Stock Units · Derivative | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-029001 · a4.xml · derivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,592 Underlying: Common Stock · 4,990 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:58 UTC |
LUDWIG EDWARD JDirector
|
GrantDeferred Stock Units · Derivative | 4,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028962 · a4.xml · derivative · entry 2 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,673 Underlying: Common Stock · 4,181 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: Reflects a value of $155,000 divided by the closing price of common stock on the date of grant. F5 · derivative.exercise_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F5 · derivative.expiration_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:58 UTC |
LUDWIG EDWARD JDirector
|
GrantDeferred Stock Units · Derivative | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028962 · a4.xml · derivative · entry 1 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,492 Underlying: Common Stock · 4,990 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:53 UTC |
Dockendorff Charles JDirector
|
GrantCommon Stock | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028960 · a4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,099 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:27 UTC |
Sununu John EDirector
|
GrantCommon Stock | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028927 · a4.xml · nonDerivative · entry 1 Sununu John E · CIK 0001458974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,255 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:25 UTC |
ROUX DAVID JDirector
|
GrantCommon Stock | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028926 · a4.xml · nonDerivative · entry 1 ROUX DAVID J · CIK 0001234273 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,005 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:24 UTC |
FUJIMORI YOSHIAKIDirector
|
GrantDeferred Stock Units · Derivative | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028923 · a4.xml · derivative · entry 1 FUJIMORI YOSHIAKI · CIK 0001233160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,111 Underlying: Common Stock · 4,990 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:25 UTC |
JAMES DONNADirector
|
GrantDeferred Stock Units · Derivative | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028924 · a4.xml · derivative · entry 1 JAMES DONNA · CIK 0001197735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,484 Underlying: Common Stock · 4,990 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:23 UTC |
Connors Nelda JDirector
|
GrantCommon Stock | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028921 · a4.xml · nonDerivative · entry 1 Connors Nelda J · CIK 0001478748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,432 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:20 UTC |
Zane Ellen MDirector
|
GrantCommon Stock | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028918 · a4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,043 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 05, 2019 Filed May 7, 2019 20:01 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 1,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-027494 · a4.xml · derivative · entry 3 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,526 shares Expires 2019-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on May 5, 2015. Read SEC document |
| May 05, 2019 Filed May 7, 2019 20:01 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Tax withholdingCommon Stock | 484 | $37.20 | $18,004.80 |
DisclosureSEC source: 0001104659-19-027494 · a4.xml · nonDerivative · entry 2 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,469 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 05, 2019 Filed May 7, 2019 20:01 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 1,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-027494 · a4.xml · nonDerivative · entry 1 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 02, 2019 Filed Jul 2, 2019 20:07 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
GiftCommon Stock | 1,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-009819 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,835 Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-19-007570 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual increments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $37.10 | $185,500.00 |
DisclosureSEC source: 0001225208-19-007570 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-19-007570 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC |
Mackey Edward FEVP, Operations
|
SaleCommon Stock | 55,320 | $36.83 | $2,037,297.30 |
DisclosureSEC source: 0001225208-19-007571 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,117 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.575 to $37.14, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 20:26 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
SaleCommon Stock | 1,186 | $38.10 | $45,186.60 |
DisclosureSEC source: 0001225208-19-006911 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,113 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 20:24 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,039 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-006846 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,077 Underlying: Common Stock · 3,039 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual increments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 20:24 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
SaleCommon Stock | 3,039 | $37.81 | $114,904.59 |
DisclosureSEC source: 0001225208-19-006846 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,469 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 20:24 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 3,039 | $7.41 | $22,518.99 |
DisclosureSEC source: 0001225208-19-006846 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:26 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
SaleCommon Stock | 2,011 | $37.81 | $76,035.91 |
DisclosureSEC source: 0001225208-19-006911 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,299 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 20:20 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-19-006107 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual increments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 20:20 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $38.82 | $194,100.00 |
DisclosureSEC source: 0001225208-19-006107 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 20:20 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-19-006107 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:18 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 14,400 | $39.12 | $563,263.20 |
DisclosureSEC source: 0001225208-19-005485 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.77, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:18 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 339 | $39.82 | $13,498.98 |
DisclosureSEC source: 0001225208-19-005485 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,601 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 20:22 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,038 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-005415 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,116 Underlying: Common Stock · 3,038 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual increments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 20:22 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
SaleCommon Stock | 3,038 | $40.11 | $121,854.18 |
DisclosureSEC source: 0001225208-19-005415 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,469 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 20:22 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 3,038 | $7.41 | $22,511.58 |
DisclosureSEC source: 0001225208-19-005415 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 20:13 UTC |
Brennan Daniel J.EVP and CFO
|
SaleCommon Stock | 46,360 | $40.02 | $1,855,545.09 |
DisclosureSEC source: 0001225208-19-005357 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,960 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.875 to $40.23, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 20:14 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,219 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-19-005199 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,220 Underlying: Common Stock · 24,219 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 20:14 UTC |
Carruthers WendySVP, Human Resources
|
SaleCommon Stock | 24,219 | $40.00 | $968,760.00 |
DisclosureSEC source: 0001225208-19-005199 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,339 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 20:14 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 24,219 | $7.39 | $178,978.41 |
DisclosureSEC source: 0001225208-19-005199 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 20:15 UTC |
Mackey Edward FEVP, Operations
|
SaleCommon Stock | 35,906 | $39.72 | $1,426,186.32 |
DisclosureSEC source: 0001225208-19-005111 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,437 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 20:17 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 29,412 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001225208-19-005112 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,412 shares Expires 2021-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in whole on March 7, 2015, the fourth anniversary of the grant. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 20:17 UTC |
Carruthers WendySVP, Human Resources
|
SaleCommon Stock | 29,412 | $39.63 | $1,165,676.97 |
DisclosureSEC source: 0001225208-19-005112 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,339 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.52 to $39.73, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 20:17 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 29,412 | $7.47 | $219,707.64 |
DisclosureSEC source: 0001225208-19-005112 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 21:31 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 1,357 | $40.25 | $54,619.25 |
DisclosureSEC source: 0001225208-19-004892 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,940 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 21:08 UTC |
Brennan Daniel J.EVP and CFO
|
SaleCommon Stock | 64,223 | $40.84 | $2,622,552.63 |
DisclosureSEC source: 0001225208-19-004586 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,320 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.70 to $41.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:31 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionDeferred Stock Units · Derivative | 3,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004345 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,809 Underlying: Common Stock · 3,603 shares Expires 2022-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:31 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Tax withholdingCommon Stock | 1,643 | $40.75 | $66,952.25 |
DisclosureSEC source: 0001225208-19-004345 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,868 Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:31 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionCommon Stock | 3,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004345 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:29 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionDeferred Stock Units · Derivative | 3,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004340 · doc4.xml · derivative · entry 4 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,909 Underlying: Common Stock · 3,302 shares Expires 2022-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:29 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Tax withholdingCommon Stock | 1,506 | $40.75 | $61,369.50 |
DisclosureSEC source: 0001225208-19-004340 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,368 F3 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:29 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 3,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004340 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 21:08 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionDeferred Stock Units · Derivative | 19,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004585 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,227 Underlying: Common Stock · 19,226 shares Expires 2020-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 2, 2016, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 2, 2016, the first anniversary of the date of grant. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 21:08 UTC |
Mackey Edward FEVP, Operations
|
Tax withholdingCommon Stock | 8,546 | $40.75 | $348,249.50 |
DisclosureSEC source: 0001225208-19-004585 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,343 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.